Literature DB >> 11898526

Spectrum and classification of inflammatory demyelinating diseases of the central nervous system.

B Kalman1, F D Lublin.   

Abstract

The aim of this review is to highlight recent observations concerning the pathogenesis of acute and chronic inflammatory demyelinating diseases in the central nervous system. Without attempting to provide a didactic classification or a complete survey, we emphasize the discriminative nature of new clinical, imaging, and immunopathologic data, which, even in the absence of specific molecular markers, modify our views about the nosologic relations among these overlapping clinicopathologic entities. In the light of new findings, multiple sclerosis may represent a spectrum of demyelinating diseases rather than a single entity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11898526     DOI: 10.1007/s11910-001-0027-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  52 in total

1.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

2.  Recurrent acute transverse myelopathy associated with anticardiolipin antibodies.

Authors:  A Campi; M Filippi; G Comi; G Scotti
Journal:  AJNR Am J Neuroradiol       Date:  1998-04       Impact factor: 3.825

3.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Authors:  L Truyen; J H van Waesberghe; M A van Walderveen; B W van Oosten; C H Polman; O R Hommes; H J Adèr; F Barkhof
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

4.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

5.  Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions.

Authors:  S Narayanan; L Fu; E Pioro; N De Stefano; D L Collins; G S Francis; J P Antel; P M Matthews; D L Arnold
Journal:  Ann Neurol       Date:  1997-03       Impact factor: 10.422

6.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.

Authors:  S E Baranzini; M C Jeong; C Butunoi; R S Murray; C C Bernard; J R Oksenberg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

7.  Devic's neuromyelitis optica: a clinicopathological study of 8 patients.

Authors:  R N Mandler; L E Davis; D R Jeffery; M Kornfeld
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

8.  A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?

Authors:  D Karussis; R R Leker; A Ashkenazi; O Abramsky
Journal:  Ann Neurol       Date:  1998-10       Impact factor: 10.422

9.  Serial magnetization transfer imaging to characterize the early evolution of new MS lesions.

Authors:  N C Silver; M Lai; M R Symms; G J Barker; W I McDonald; D H Miller
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

10.  Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

Authors:  M Kerschensteiner; E Gallmeier; L Behrens; V V Leal; T Misgeld; W E Klinkert; R Kolbeck; E Hoppe; R L Oropeza-Wekerle; I Bartke; C Stadelmann; H Lassmann; H Wekerle; R Hohlfeld
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

View more
  1 in total

1.  Peripheral third cranial nerve enhancement in multiple sclerosis.

Authors:  M Tariq Bhatti; Ilona M Schmalfuss; Lorna S Williams; Ronald G Quisling
Journal:  AJNR Am J Neuroradiol       Date:  2003-08       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.